Mylan N.V. (NASDAQ:MYL) saw a significant drop in short interest in the month of October. As of October 13th, there was short interest totalling 25,991,685 shares, a drop of 8.4% from the September 29th total of 28,385,090 shares. Currently, 5.1% of the company’s stock are short sold. Based on an average daily volume of 8,430,511 shares, the days-to-cover ratio is presently 3.1 days.
Institutional investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of Mylan N.V. by 19.8% in the second quarter. FMR LLC now owns 813,267 shares of the company’s stock worth $31,572,000 after purchasing an additional 134,258 shares during the last quarter. Swiss National Bank raised its stake in shares of Mylan N.V. by 3.1% in the second quarter. Swiss National Bank now owns 1,661,842 shares of the company’s stock worth $64,513,000 after purchasing an additional 50,100 shares during the last quarter. Vivaldi Asset Management LLC purchased a new stake in shares of Mylan N.V. in the second quarter worth approximately $5,098,000. Advisors Capital Management LLC raised its stake in shares of Mylan N.V. by 4.7% in the second quarter. Advisors Capital Management LLC now owns 86,329 shares of the company’s stock worth $3,351,000 after purchasing an additional 3,854 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of Mylan N.V. by 508.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 73,842 shares of the company’s stock worth $2,867,000 after purchasing an additional 61,712 shares during the last quarter. 71.98% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on MYL shares. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Royal Bank Of Canada set a $41.00 price target on Mylan N.V. and gave the stock a “hold” rating in a research report on Sunday, July 16th. Citigroup Inc. raised Mylan N.V. from a “neutral” rating to a “buy” rating and raised their price target for the stock from $36.00 to $42.00 in a research report on Wednesday, August 16th. Cowen and Company reaffirmed a “hold” rating and set a $43.00 price target on shares of Mylan N.V. in a research report on Thursday, August 3rd. Finally, BidaskClub raised Mylan N.V. from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $41.21.
Mylan N.V. (NASDAQ:MYL) opened at 38.35 on Monday. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87. The firm has a 50-day moving average price of $35.12 and a 200-day moving average price of $36.26. The company has a market capitalization of $20.57 billion, a P/E ratio of 31.00 and a beta of 1.30.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the company earned $1.16 earnings per share. On average, analysts forecast that Mylan N.V. will post $4.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/10/30/mylan-n-v-myl-short-interest-down-8-4-in-october.html.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.